April 4, 2022 -- Cha Medical & Bio Group has begun construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. The facility will be a 710,000 sq ft manufacturing site for cell and gene therapies, as well as a site for stem cell biobanking. The $250 million project is expected to be completed by the end of 2024, the company said.
The CGB facility will provide contract development and manufacturing (CDMO) services and isolated cleanrooms to optimize the manufacturing of mRNA, viral vectors, and plasmid DNA following good manufacturing practice guidelines, the company said.
Furthermore, Cha said that these services will be complemented by the company's implementation of cell separation, cell culture, and cryopreservation technologies. The facility will also contain a stem cell biobank for storage of various cell types such as stem cells, natural killer cells, cord blood, sperm cells, and egg cells.
The company said that the site will serve to expand its CDMO network across Asia, specifically addressing the unique requirements for cell and gene therapy manufacturing.
Cell Gene Biobank in Pangyo, Korea. Image courtesy of Cha Medical & Bio Group.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
